Drug Potency Efficacy
Drug Potency Efficacy - Related Videos
01:22
Dose-Response Relationship: Potency and Efficacy
0 Views •
2023
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
09:49
Use of a Battery of Chemical and Ecotoxicological Methods for the Assessment of the Efficacy of Wastewater Treatment Processes to Remove Estrogenic Potency
0 Views •
Cited by 7 •
2016
Endocrine Disrupting Compounds (EDC) pose a substantial risk to the aquatic environment. Municipal wastewater treatment plants are major contributors to the estrogenic potency of surface waters. The methodology provided in this paper allows for an assessment of the efficacy and suitability of wastewater treatment processes with respect to EDC removal.
02:48
Determining Antiviral Efficacy of Experimental Drugs Through a Plaque Assay
0 Views •
2025
This video demonstrates the method to perform a plaque assay using a virus obtained from infected porcine cornea. The porcine cornea is used to test the antiviral efficacy of experimental drugs.
08:06
Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
0 Views •
Cited by 1 •
2016
Peptide adsorption to plasticware during traditional tip-based serial dilutions can significantly impact potency determination and confound the understanding of structure-activity relationships used for lead identification and lead optimization phases of drug discovery. Here methods for automated acoustic non-contact serial dilution of peptide samples are described.
05:14
An Assay to Evaluate Drug Efficacy against a Mycobacterium tuberculosis Infection Model
0 Views •
2025
This video demonstrates an assay to evaluate the efficacy of drugs against Mycobacterium tuberculosis (Mtb) infection. An in vitro infection model containing Mtb/macrophage aggregates is generated that mimics in vivo infection. Upon introducing suitable antibiotics, their efficacy is tested via resuzarin assay to monitor the survival of bacteria with increasing drug concentrations.
FAQs
A potency difference does not necessarily indicate a difference in therapeutic capacity. When two medicines are evaluated against the same specified effect, one may reach that effect at a lower dose while both ultimately produce the same maximum response. Conversely, a medicine may produce a greater maximum response even if it requires more drug to do so.
Full and partial agonists are distinguished by the size of the response they can generate, not simply by the dose at which they act. A partial agonist can show activity at a given dose yet have a lower maximum effect than a full agonist. This distinction helps interpret why dose escalation may not produce equivalent clinical responses.
Dose-response and concentration-response curves allow potency and efficacy to be examined together. The position associated with a specified effect informs how much drug is needed, while the highest response shown by the curve indicates the drug’s ceiling. Reading both features prevents researchers from treating a lower required dose as evidence of a greater maximum effect.
In clinical research, investigators compare these properties when selecting doses for study or treatment. They can examine whether a candidate reaches the desired response at a lower dose, whether its maximum response is sufficient, and whether observed adverse effects alter the practical choice. This approach links dose selection with both expected benefit and adverse effects.
Treatment optimization requires considering potency and efficacy together rather than maximizing either property alone. A highly potent medicine may act at a lower dose, but the clinically relevant question also includes the response it can produce. Comparing the two measures helps researchers interpret therapeutic effects alongside adverse effects and select a more appropriate treatment strategy.
When medicines are compared in clinical research, dose-response findings can reveal whether their differences reflect dose requirements, maximum response, or agonist behavior. These distinctions support clearer interpretation of therapeutic and adverse effects and help prevent an apparent potency advantage from being mistaken for superior overall efficacy. The same framework also guides comparisons between full and partial agonists.